Keratoacanthoma
☆ Ing asil Stiftung Warentest 2022 saka Jerman, kepuasan konsumen karo ModelDerm mung luwih murah tinimbang konsultasi telemedicine sing dibayar.
Khas Keratoacanthoma
References
Keratoacanthoma (KA) minangka tumor kulit sing kerep dikenal amarga tuwuh kanthi cepet lan potensial mundur dhewe. Biasane kedadeyan ing wong sing luwih tuwa, kulit putih kanthi riwayat karusakan srengenge. Nalika ngilangi bedhah nggunakake eksisi utawa operasi mikrografi Mohs minangka perawatan biasa, ana macem-macem pilihan terapi liyane sing kasedhiya.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) minangka tumor kelas rendah sing diwiwiti ing kelenjar tartamtu ing kulit lan katon kaya squamous cell carcinoma (SCC) ing mikroskop. Ana debat sing terus-terusan babagan apa KA kudu diklasifikasikake minangka wangun SCC invasif.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) minangka jinis kanker paling umum nomer loro ing wong, utamane ing antarane wong tuwa. Bedah biasane digunakake kanggo ngobati cSCC, nanging kanggo sawetara pasien sing ora bisa operasi utawa milih ora, opsi liyane kaya perawatan intralesi bisa dianggep. Pangobatan intralesi tradisional (methotrexate or 5-fluorouracil) wis digunakake, nanging isih ana riset babagan pendekatan anyar kayata immunotherapy intralesi lan virotherapy oncolytic. Ing kene, kita bakal ndeleng macem-macem perawatan intralesi kanggo cSCC, wiwit saka metode klasik nganti strategi mutakhir.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Ing mikroskop, keratoacanthoma meh padha karo karsinoma sel skuamosa. Nalika sawetara ahli patologi nggolongake keratoacanthoma minangka entitas sing béda lan dudu ganas, kira-kira 6% saka keratoacanthoma klinis lan histologis ngalami kemajuan dadi kanker sel skuamosa invasif lan agresif.
○ Diagnosis lan Perawatan
#Dermoscopy
#Skin biopsy